Investor Presentaiton
LOVVOLUS
HIGHLIGHTS
A HIGHLY COMPETITIVE FILLER LINE
•
Evolysse™ - a first-generation cold technology Hyaluronic Acid line
·
5 fillers in late-stage clinical development
Indications including mid face, nasolabial folds, lips and eyes
• In partnership with Symatese, developer of the latest generation of
Restylane® products in the U.S.
•
RAISING 2028 REVENUE OUTLOOK FROM $500M TO $700M
Increasing guidance by $200M in 2028 based on product launches
in 2025, 2026 and 2027
A HIGHLY CAPITAL EFFICIENT AGREEMENT
• Minimal short-term dilution delivering material long-term value accretion
• Funded to profitability with $50M Pharmakon tranche
•
Leverage existing sales force, digital infrastructure, Evolus Rewards
and co-branded media
769
DView entire presentation